Finasteride, a Type 2 5α-reductase inhibitor, in the treatment of men with androgenetic alopecia

Bibliography

• OLSEN EA: Androgenetic alopecia. In: Disorders of Hair Growth: Diagnosis and Treatment. Olsen EA (Ed.), McGraw-Hill Inc., New York, USA (1990257–283.
   Google Scholar
• ••A thorough review of androgenetic alopecia in men andwomen.
   Google Scholar
• RHODES T, GIRMAN CJ, SAVIN RC et al: Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg. (1998) 24:1330–32.
   PubMed Web of Science ®Google Scholar
• •This study gives up-to-date prevalence figures for men with androgenetic alopecia.
   Google Scholar
• DAWBER RPR, VAN NESTE D: Psychosociology of hair. In: Hair, and Scalp Disorders. Common Presenting Signs, Differential Diagnosis and Treatment. Dawber R, Van Neste D (Eds.), JB Lippincott Co., Philadelphia, USA (1995):245–252.
   Google Scholar
• CASH TF: Losing hair, losing points?: the effects of male pattern baldness on social impression formation. J. App. Social Psy. (1990) 20(2):154–167.
   Web of Science ®Google Scholar
• ••A study showing the psychosocial significance of androge-netic alopecia, demonstrating that the condition is more than aesthetics.
   Google Scholar
• CASH TF, PRICE VH, SAVIN RC: Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J. Am. Acad. Dermatol. (1993) 29(4)568–575.
   Google Scholar
• US package insert for Rogaine (minoxidil topical so-lution). Physicians' Desk Reference. 50th Edition. Medical Economics Company, Inc., Montvale, NJ, USA (1996)2637–2641 .
   Google Scholar
• OLSEN EA, WEINER MS, AMARA IA, DELONG ER: Five year follow-up of men with androgenetic alopecia treated with topical minoxidil. J. Am. Acad. Dermatol (1990) 22 (4):643–646.
   PubMed Web of Science ®Google Scholar
• •This study documents long-term follow-up of patients treated with topical minoxidil.
   Google Scholar
• SIMPSON NB, BARTH JH: Hair patterns: hirsuites and baldness. In: Diseases of the Hair and Scalp. Dawber R (Ed.), Blackwell Science Ltd., London, UK (1997):67–122.
   Google Scholar
• ••A comprehensive chapter on all aspects of androgeneticalopecia and its hormone control.
   Google Scholar
• SADICK NS, RICHARDSON DC: Surgical procedures. In: Consumer Reports Books. Your Hair, Helping to Keep it. Treatment and Prevention of Hair Loss for Men and Women. Consumers Union of United States, Inc., Yonkers, NY, USA (1992):114–139.
   Google Scholar
• IMPERATO-MCGINLEY J, GUERRERO L, GAUTIER T, PE-TERSON RE: Steroid 5a-reductase deficiency in man: aninherited form of male pseudohermaphroditism. Sci-ence (1974) 186:1213–1215.
   PubMed Web of Science ®Google Scholar
• ••This and reference [11] are the first reports of genetic5a-reductase deficiency.
   Google Scholar
• WALSH PC, MADDEN JD, HARROD MJ, GOLDSTEIN JL, MACDONALD PC, WILSON JD: Familial incomplete male pseudohermaphroditism, Type 2: decreased dihydro-testosterone formation in pseudovaginal perineoscro-tal hypospadias. New Engl. J. Med. (1 9 7 4) 291(18)944–949.
   Google Scholar
• ••This and reference [10] are the first reports of genetic5a-reductase deficiency.
   Google Scholar
• IMPERATO-MCGINLEY J: 5a-reductase-2 deficiency. Curr. Ther. Endocrinol. Metab. (1997) 6:384–387.
   PubMedGoogle Scholar
• ANDERSSON S, BERMAN DM, JENKINS EP, RUSSELL DW: Deletion of steroid 5a-reductase 2 gene in male pseu-dohermaphroditism. Nature (1991) 354:159–161.
   PubMed Web of Science ®Google Scholar
• •Molecular genetic analysis confirming Type 2 5a-reductase is the affected isoenzyme in 5a-reductase deficiency.
   Google Scholar
• HARRIS G, AZZOLINA B, BAGINSKY W et al: Identifica- tion and selective inhibition of an isozyme of steroid 5a-reductase in human scalp. Proc. Nati Acad. Sci. USA (1992) 89:10787–10791.
   PubMed Web of Science ®Google Scholar
• •Characterisation of the human Type 1 5a-reductase isoenzyme. RUSSELL DW, WILSON JD: Steroid 5a-reductase: two genes/two enzymes. Ann. Rev. Biochem. (1994) 63:25-61. Comprehensive review of the 5a-reductase enzyme system. THIGPEN AE, SILVER RI, GUILEYARDO JM, CASEY ML, MCCONNELL JD, RUSSELL DW: Tissue distribution and ontogeny of steroid 5a-reductase isozyme expression. Clin. Invest. (1993) 92:903-910. Describes differential expression of the two 5a-reductase isoenzymes by tissue type and developmental stage.
   Google Scholar
• EICHELER W, DREHER M, HOFFMANN R, HAPPLE R, MUL- LER G: Immunohistochemical evidence for differential distribution of 5a-reductase isoenzymes in human skin. Br. J. Dermatol (1995) 133:371–376.
   PubMed Web of Science ®Google Scholar
• •This and reference [18] describe location of 5a-reductase isoenzymes in human scalp hair follicles using antibodies.
   Google Scholar
• BAYNE EK, FLANAGAN J, EINSTEIN M et al.: Immunohis- tochemical localization of types 1 and 2 5a-reductase in human scalp. Br. J. Dermatol. (1999): (In Press).
   Google Scholar
• •This and reference [17] describe location of 5a-reductase isoenzymes in human scalp hair follicles using antibodies.
   Google Scholar
• GORMLEY GJ, STONER E, BRUSKEWITZ RC et al: The ef- fect of finasteride in men with benign prostatic hyper-plasia. New Engl. J. Med. (1992) 327:1185–1191.
   PubMed Web of Science ®Google Scholar
• MCCONNELL JD, BRUSKEWITZ R, WALSH P et al: The ef- fect of finasteride on the risk of acute urinary reten-tion and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl. J. Med. (1998) 338:557–563.
   PubMed Web of Science ®Google Scholar
• RITTMASTER RS: Finasteride. New Engl. J. Med. (1994)330 (2) :120–125.
   PubMed Web of Science ®Google Scholar
• PRICE VH: Testosterone metabolism in the skin. Arch. Dermatol. (1975) 111:1496–1502.
   PubMed Web of Science ®Google Scholar
• •Early review of androgens and skin, with attention to puta-tive role of DHT in hair and skin disorders.
   Google Scholar
• KAUFMAN KD: Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol. Clin. (1996) 14 (0697–711.
   PubMed Web of Science ®Google Scholar
• KLIGMAN AM: The comparative histopathology of male-pattern baldness and senescent baldness. In: Clinics in dermatology 6th edtion. DeVillez RL, Griggs LMP, Freeman B (Eds.), JB Lippincott, Philadelphia, USA (1988) :108–118.
   Google Scholar
• WHITING DA: The value of horizontal sections of scalp biopsies. J. Cutan. Ageing Cosmetic Dermatol (1990) 1(3):165–173.
   Google Scholar
• WHITING DA: Diagnostic and predictive value of hori- zontal sections of scalp biopsy specimens in male pat-tern androgenetic alopecia. J. Am. Acad. Dermatol (1993) 28(5 Pt 1):755–763.
   Google Scholar
• ••This paper demonstrates that histologic findings can besemiquantitated, providing objective support to clinical findings in androgenetic alopecia.
   Google Scholar
• LIANG T, RASMUSSON GH, BROOKS JR: Biochemical and biological studies with 4-aza-steroidal 5a-reductase in- hibitors. J. Steroidal Biochem. (1983) 19(1) :385–390.
   PubMedGoogle Scholar
• ••Description of the class of synthetic 5a-reductase inhibitorsto which finasteride belongs.
   Google Scholar
• LIANG T, HEISS CE, CHEUNG AH, REYNOLDS GF, RAS- MUSSON GH: 4-azasteroidal 5a-reductase inhibitors without affinity for the androgen receptor. J. Biol. Chem. (1984) 259(2):734–739.
   PubMed Web of Science ®Google Scholar
• GORMLEY GJ, STONER E, RITTMASTER RS et al.: Effects of finasteride (MK-906), a 5a-reductase inhibitor, on cir-culating androgens in male volunteers. J. Clin. Endocri-nol Metab. (1990) 70(01136–1141.
   PubMed Web of Science ®Google Scholar
• RITTMASTER RS, LEMAY A, ZWICKER H et al.: Effect of fi- nasteride, a 5a-reductase inhibitor, on serum gonado-tropins in normal men. J. Clin. Endocrinol. Metab. (1992) 75 (2) :484–488.
   PubMed Web of Science ®Google Scholar
• DALLOB AL, SADICK NS, UNGER W eta].: The effect of fi- nasteride, a 5a-reductase inhibitor, on scalp skin tes-tosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J. Clin. Endocrinol. Metab. (1994) 79(3):703–706.
   Google Scholar
• ••Initial study demonstrating the ability of finasteride to sup-press scalp DHT in balding men.
   Google Scholar
• WALDSTREICHER J, FIEDLER V, HORDINSKY M et al.: Ef- fects of finasteride on dihydrotestosterone content of scalp skin in men with male pattern baldness. J. Invest. Dermatol. (1994) 102 (4) :615.
   Web of Science ®Google Scholar
• RHODES L, HARPER J, UNO H et al.: The effects of finaste- ride (PROSCAR) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Maraca arctoi-des). J. Gun. Endocrinol. Metab. (1994) 79(4):991–996.
   PubMed Web of Science ®Google Scholar
• •Study of finasteride in an animal model of androgenetic alopecia.
   Google Scholar
• OHTAWA M, MORIKAWA H, SHIMAZAKI J: Pharmacoki-netics and biochemical efficacy after single and multi-ple oral administration of N-(2-methyl-2-propyl) -3- oxo -4 -aza-5 a-andr ost-1 -ene -17 p-carbox-amide, a new type of specific competitive inhibitor of testosterone 5a-reductase, in volunteers. Eur. J. Drug Metab. Pharmacokin. (1991) 16(1):15–21.
   PubMed Web of Science ®Google Scholar
• CARLIN JR, HOGLUND P, ERIKSSON L-0 et al.: Disposi-tion and pharmacokinetics of [14C] finasteride after oral administration in humans. Drug Metab. Dispos. (1992) 20(2):148–155.
   Google Scholar
• HUSKEY SW, DEAN DC, MILLER RR, RASMUSSON GH, CHIU SHL: Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative me-tabolism of finasteride. Drug Metab. Dispos. (1995) 23(101126–1135.
   Google Scholar
• US package insert for Propecia- (finasteride 1 mg tab-lets). Physicians' Desk Reference. 52nd edition. Medical Economics Company, Inc., Montvale, NJ, USA (1998):A53–A56.
   Google Scholar
• KAUFMAN KD: Clinical studies on the effects of oral fi-nasteride, a Type II 5a-reductase inhibitor, on scalp hair in men with male pattern baldness. In: Hair re-search for the next millennium. Proceedings of the First Tr-continental Meeting of Hair Research Societies; 8–10 Oct. 1995. Brussels (Belgium).V an Neste D, Randall VA (Eds.), Elsevier Science By, Amsterdam, Netherlands (1996)363–365.
   Google Scholar
• KAUFMAN KD, OLSEN EA, WHITING D et al.: Finasteride in the treatment of men with androgenetic alopecia. J. Am. Acad. Dermatol. (1998) 39:578–589.
   PubMed Web of Science ®Google Scholar
• ••Results of two-year, placebo-controlled studies of finaste-ride in 1553 men with vertex male pattern hair loss.
   Google Scholar
• LEYDEN J, DUNLAP F, MILLER B et al.: Finasteride in the treatment of men with frontal male pattern hair loss. J. Am. Acad. Dermatol. (1999): (In Press).
   Google Scholar
• •Results of 1-year, placebo-controlled study and its open-label extension demonstrating the effect of finasteride in men with male pattern hair loss outside the vertex area.
   Google Scholar
• ROBERTS J, HORDINSKY M, OLSEN E et al.: The effects of finasteride in post-menopausal women with androge-netic alopecia. Hair Workshop, Brussels, Belgium, 2–3 May (1998): 16.
   Google Scholar
• •Abstract of a one-year, placebo-controlled study demon-strating the lack of effect of finasteride in postmenopausal women with androgenetic alopecia.
   Google Scholar
• VAN HECKEN A, DEPRE M, SCHWARTZ JI et al.: Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5a-reductase inhibitor, in healthy subjects. Eur. J. Clin. Pharmacol. (1994) 46:123–126.
   PubMed Web of Science ®Google Scholar
• LEVY MA, BRANDT M, SHEEDY KM et al.: Epristeride is a selective and specific uncompetitive inhibitor of hu-man steroid 5a-reductase isoform 2.1 Steroid Biochem. Molec. Biol. (1994) 48:197–206.
   Google Scholar
• NAKAYAMA 0, HIROSUMI J, CHIDA N et al.: FR146687, a novel steroid 5a-reductase inhibitor: in vitro and in vivo effects on prostates. Prostate (1997) 31:241–249.
   Google Scholar
• JONES CD, AUDIA JE, LAWHORN DE et al.: Nonsteroidal inhibitors of human Type 1 steroid 5a-reductase. J. Med. Chem. (1993) 36:421–423.
   PubMed Web of Science ®Google Scholar
• HIRSCH KS, JONES CD, AUDIA JE et al.: LY191704: a selective, nonsteroidal inhibitor of human steroid 5a-reductase Type 1. Proc. Natl. Acad. Sci. USA (1993) 90:5277–5281.
   PubMed Web of Science ®Google Scholar
• ELLS WORTH K, AZZOLINA B, BAGINSKY W et al.: MK386:a potent, selective inhibitor of the human Type 1 5a-reductase. J. Steroid. Biochem. Mol. Biol. (1996) 58:377–384.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ JI, TANAKA WK, WANG DZ et al.: MK-386, an inhibitor of 5a-reductase Type 1, reduces dihydrotes-tosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in se-men. J Clin. Endocrinol Metab. (1996) 82:1373–1377.
   Web of Science ®Google Scholar
• •Study demonstrating that administration of a Type 1 5a-reductase inhibitor in man suppresses sebum DHT.
   Google Scholar
• SCHWARTZ JI, VAN HECKEN A, DE SCHEPPER PJ et al.: Ef- fect of MK-386, a novel inhibitor of Type 1 5a-redu-ctase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men. J. Clin. Endocrinol. Metab. (1996) 81:2942–3947.
   Google Scholar
• •Study demonstrating effect on serum DHT of a Type 1 5a-reductase inhibitor added to finasteride.
   Google Scholar
• BAKSHI RK, RASMUSSON GH, PATEL GF et al.: 4-aza-3-oxo-a5-androst-1-ene-17b-N-aryl-carboxamides as dual inhibitors of human Type 1 and Type 2 steroid 5a-reductases. Dramatic effect of N-aryl substituents on Type 1 and Type 2 5a-reductase inhibitory potency. J. Med. Chem. (1995) 38:3189–3192.
   Google Scholar
• KOJO H, NAKAYAMA 0, HIROSUMI J, CHIDA N, NOTSU Y, OKUHARA M: Novel steroid 5a-reductase inhibitor FK143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes. Mol. Pharmacol. (1995) 48:410–406.
   Google Scholar
• BRAMSON HN, HERMANN D, BATCHELOR KW, LEE FW, JAMES MK, FRYE SV: Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J. Pharmacol Exp. Ther. (1997) 282:1496–1502.
   PubMed Web of Science ®Google Scholar
• HERMANN DJ, DAVIS IM, WILSON TH: Effects of GI198745 (GG745), a novel 5a-reductase (5AR) inhibi-tor, on dihydrotestosterone (DHT). Am. Soc. Clin. Pharm. Ther. (1996) 59:162.
   Google Scholar
• HOBBS S, HERMANN DJ, GABRIEL T, WILSON B, MORRILL R, CLARK RV: Marked suppression of dihydrotestoster-one in men by a novel 5 alpha reductase inhibitor. Fer-til. Steril. (1998) 70 (Suppl. 3):S455. Keith D Kaufmann & Rodney P Dawber2 tAuthor for correspondence Merck & Co., Inc., Merck Research Labs, PO Box 2000, Rahway, NJ 07065, USA2Department of Dermatology, The Churchill Hospital, Old Road, Headington, Oxford, England, 0X3 7LJ, UK
   Google Scholar